Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 464 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intact Clear all
Completed Not applicable Interventional

Cleaner Air for Lower Cardiometabolic Risk

NCT05994937
View directory record Official record
Conditions
PreDiabetes
Interventions
PAC with HEPA filter intact, PAC with HEPA filter removed
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Not applicable Interventional Results available

Optical Frequency Domain Imaging (OFDI) and Vascular Healing After Stent Placement

NCT01794949
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Resolute Integrity stent
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults

NCT02757755
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AB-SA01 (10^8 PFU per phage), AB-SA01 (10^9 PFU per phage), Placebo (for Cohort 10^8), Placebo (for Cohort 10^9)
Biological
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 21, 2026, 5:04 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Clinical Evaluation of Bedside Pulse Lavage Irrigation Device

NCT01457183
View directory record Official record
Conditions
Healthy
Interventions
Pulsed lavage (Stryker Pulsavac Plus)
Device
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

NCT03248570
View directory record Official record
Conditions
Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer
Interventions
Pembrolizumab, Chemotherapy
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 21, 2026, 5:04 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

NCT07392723
View directory record Official record
Conditions
Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of, Brain Aging, Fatty Acids, Omega-3
Interventions
Alpha-Linolenic Acid (2.6 g/day), Placebo Control Group
Drug · Dietary Supplement
Lead sponsor
Michal Schnaider Beeri, Ph.D.
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 21, 2026, 5:04 PM EDT
Recruiting Phase 4 Interventional

Evaluating Intact Fish Skin Graft and Standard of Care Versus Standard of Care Alone in Nonhealing Venous Leg Ulcers

NCT06693570
View directory record Official record
Conditions
Venous Leg Ulcer (VLU), Venous Leg Ulcers, Venous Leg, Nonhealing Venous Leg Ulcer
Interventions
Intact Fish Skin Graft (IFSG) + Standard of Care, Standard of Care
Other
Lead sponsor
Kerecis Ltd.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 21, 2026, 5:04 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Trans-abdominal Fetal Pulse Oximetry: Signal Integrity

NCT04081623
View directory record Official record
Conditions
Fetal Distress
Interventions
Raydiant Oximetry Sensing System
Device
Lead sponsor
Raydiant Oximetry, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 21, 2026, 5:04 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

NCT04064827
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
Interventions
Paricalcitol
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 9 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
14
States / cities
Little Rock, Arkansas • Redwood City, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 21, 2026, 5:04 PM EDT
Recruiting No phase listed Observational

Evaluation of Clinical Outcomes and Acceptability of an Anatomical Classification for Placenta Accreta Spectrum

NCT07283042
View directory record Official record
Conditions
Placenta Accreta
Interventions
Total Hysterectomy, Modified subtotal hysterectomy, One-Step Conservative Surgery
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 21, 2026, 5:04 PM EDT
Recruiting No phase listed Observational

Trans-Rectal Ultrasound of the Female Pelvis for Real-Time MRI-US Fusion Based Needle Tracking

NCT05977621
View directory record Official record
Conditions
Uterine Cancer
Interventions
Transrectal ultrasound (TRUS)
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 21, 2026, 5:04 PM EDT
Terminated Phase 1 Interventional

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

NCT03971734
View directory record Official record
Conditions
High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma
Interventions
Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg, Regadensoson 0.4mg, Regadensoson 0.7mg, Regadensoson 1.0mg, Regadensoson 1.4mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 21, 2026, 5:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mitochondrial Dysfunction, Inflammation, and White Matter Integrity in Youth With Mood Disorders

NCT02596698
View directory record Official record
Conditions
Depression, Bipolar Disorder, Bipolar Disorder Not Otherwise Specified, Unspecified Mood Disorder
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
13 Years to 18 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 21, 2026, 5:04 PM EDT
Recruiting Not applicable Interventional

Transcranial Magnetic Stimulation for MCI

NCT05992831
View directory record Official record
Conditions
Mild Cognitive Impairment, Depression
Interventions
Accelerated iTBS, Sham Comparator
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
60 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally

NCT05572255
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Cenobamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIV

NCT02431325
View directory record Official record
Conditions
HIV
Interventions
Teduglutide, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 21, 2026, 5:04 PM EDT
Recruiting Not applicable Interventional

Pilot Trial of Spiritual Care Interventions for Patients With Cancer

NCT06811376
View directory record Official record
Conditions
Advanced Cancer
Interventions
Spiritual Care Intervention #1, Spiritual Care Intervention #2
Behavioral · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Brooklyn, New York • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 21, 2026, 5:04 PM EDT
Completed No phase listed Observational

Electromyography Evaluation of Subscapularis Function After Total Shoulder Arthroplasty

NCT00779974
View directory record Official record
Conditions
Osteoarthritis
Interventions
Evaluation
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
45 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 21, 2026, 5:04 PM EDT
Not listed Phase 1Phase 2 Interventional

Beta-Hydroxybutyrate Feasibility Treating IBD

NCT06351124
View directory record Official record
Conditions
Crohn's Disease, Inflammatory Bowel Diseases
Interventions
Feasibility of beta-hydroxybutyrate supplementation to reduce inflammation in patients with Crohn's
Biological
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 5:04 PM EDT
Terminated Not applicable Interventional Results available

Intensive Nutrition in Acute Respiratory Distress Syndrome (ARDS): A Clinical Trial (INTACT)

NCT01921101
View directory record Official record
Conditions
Acute Lung Injury
Interventions
intensive medical nutrition, control
Behavioral · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 90 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers

NCT05909553
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Not applicable Interventional Results available

A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

NCT02100722
View directory record Official record
Conditions
Coronary Disease, Coronary Stenosis
Interventions
FFR guided PCI, CABG, Resolute Integrity Stent, Resolute Onyx Stent
Procedure · Device
Lead sponsor
Stanford University
Other
Eligibility
21 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
13
States / cities
Palo Alto, California • Stanford, California • Decatur, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Are the "ounce-equivalents" in the Protein Foods Groups Really Equivalent?

NCT03142737
View directory record Official record
Conditions
Protein Metabolism
Interventions
Red kidney bean intake, Eggs intake, Peanut butter intake, Ground beef intake, Intact beef intake
Other
Lead sponsor
University of Arkansas
Other
Eligibility
20 Years to 40 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 21, 2026, 5:04 PM EDT
Terminated No phase listed Observational

A Registry Study Evaluating Outcomes in Breast Biopsy With the Intact™ Breast Lesion Excision System (BLES)

NCT03520127
View directory record Official record
Conditions
Breast Lesions
Interventions
Intact Breast Lesion Excision System (BLES)
Device
Lead sponsor
Medtronic Surgical Technologies
Industry
Eligibility
18 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Birmingham, Alabama • Atlanta, Georgia • Dalton, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 21, 2026, 5:04 PM EDT